Latest Administration News

Celsius Resources reports significant high-grade copper-gold drill results from its MCB Project in the Philippines, reinforcing confidence in the ongoing feasibility study update.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

Unith Ltd reported an 18.8% increase in FY 2025 revenue to A$5.37 million alongside a significant capital raise, positioning itself for expansion in the burgeoning AI Digital Humans market.

Advance Zintek reports a robust 26.83% revenue increase in Q1 FY26, driven by strong growth across North America, Australia, and Europe, despite regulatory hurdles impacting zinc oxide sales in Australia.

Linius Technologies has addressed a late filing of a director's interest notice, attributing the delay to an administrative oversight involving a new class of securities. The company has updated its processes and will re-brief directors to ensure future compliance.

Arovella Therapeutics has demonstrated that its novel CLDN18.2 CAR-T cells effectively eliminate pancreatic cancer cells in vitro, matching the performance of a leading competitor’s product. The company is now advancing this CAR into its innovative iNKT cell platform to tackle solid tumours.

James Bay Minerals has entered a binding agreement to acquire the high-grade Shafter Silver Project in Texas, featuring substantial existing infrastructure and a rich production history. The acquisition is backed by a $30 million capital raise and signals a strategic expansion into a premier US mining jurisdiction.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Auric Mining has completed the acquisition of the Burbanks Gold Processing Facility for $4.4 million, positioning itself to control its gold production cycle and accelerate growth.

Paradigm Biopharmaceuticals has dosed participants in its pivotal Phase 3 trial for knee osteoarthritis across the US and Australia, progressing steadily towards a mid-2026 interim analysis.

MC Mining’s FY2025 results reveal a sharp increase in losses driven by impairments and lower coal sales, while a strategic investment by Kinetic Development Group advances its flagship Makhado Project.